Deepak Lala, Tasir Haque, Hannah Feinman, Jianhong Wu, Yuren Wang, Amy Dwyer, Thu Truong and Carol Lange

Context Therapeutics, a clinical-stage biotechnology company, today announced that new preclinical data on Apristor®, its first-in-class full progesterone receptor antagonist, will be featured at the San Antonio Breast Cancer Symposium® taking place on December 4-8, 2018 in San Antonio, TX.

PHILADELPHIA--(BUSINESS WIRE)—October 11, 2018—Context Therapeutics today announced Phase 1 data for its investigational new drug, Apristor® (Onapristone extended release), an oral progesterone receptor antagonist that is being developed for progesterone receptor-positive (PR+) cancers.